Third member of US FDA advisory panel resigns over Alzheimer’s drug approval

A 3rd member of a panel of exterior advisors to the US Meals and Drug Administration resigned in protest of the company’s choice to approve remedy for Alzheimer’s illness from Biogen Inc regardless of the panel’s advice to not.

Aaron Kesselheim, a professor of medication at Harvard Medical College who has served on the Meals and Drug Administration’s Nervous System Medication Advisory Committee since 2015, instructed Reuters Thursday that he’s stepping down from the panel.

Get your FOX enterprise on the go by clicking right here

“The rationale was that the FDA wanted to re-evaluate the way it requested and used advisory committees…as a result of I did not suppose the agency suggestions from the committee on this case…have been adequately built-in into the decision-making course of,” Kesselheim mentioned in an e mail. mail.

He cited the Meals and Drug Administration’s choice to approve Sarepta Therapeutic Inc’s drug, eteplirsen, for Duchenne muscular dystrophy in 2016 as one other instance of a regulator approving a drug in opposition to suggestions of an advisory panel.

Stat Information first reported his departure.

Medical variations of the brand new Alzheimer’s drug may improve in numbers

On Tuesday, a member of the advisory group that voted in opposition to the approval, College of Washington neurologist Dr. Joel Perlmutter, resigned from the panel, citing the Meals and Drug Administration’s approval of Addhelm.

Mayo Clinic neurologist Dr. David Knopman mentioned he was resigning on Wednesday.

ribbon safety else they alter they alter %
Bahrain Islamic Financial institution Biogen, Inc. 414.71 +7.77 + 1.91%

The 11-member panel voted nearly unanimously in November that Biogen shouldn’t be accepted, citing inconclusive proof that the drug was efficient.

Click on right here to learn extra about FOX BUSINESS

The US Meals and Drug Administration (FDA) on Monday granted the drug “fast-track approval,” based mostly on proof that it might cut back potential contributing components to Alzheimer’s illness, moderately than demonstrating a transparent profit in opposition to the illness.

(Reporting by Julie Steenhuisen and Carl O’Donnell; Enhancing by Grant McCall)

Leave a Reply

Your email address will not be published. Required fields are marked *